Qlucore elects new chairman and board member
Also expands marketing and development team
Charlotte Edenius, who has extensive experience with pharmaceutical companies such as AstraZeneca and Orexo, has joined the board.
The company has also added two more staff to its marketing and development teams to help meet demand for Qlucore Omics Explorer software.
Qlucore, based in Lund, develops software which analyses data and visualises complicated structures in 3D directly on a computer screen.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
Data tool helps research on in vitro allergen testing
New research techniques using data analysis tools are helping to reduce the reliance on animal testing for the identification of skin sensitising chemicals that elicit an adverse immune response in humans. A novel cell-based assay called Genomic Allergen Rapid Detection (GARD) for the prediction of sensitising chemicals identifies markers that are involved in biological pathways with immunological relevant functions.
Research & Development
Data visualisation with the image makers
Genetic research and modern drug discovery techniques create masses of data for researchers to trawl through to find that all important scientific breakthrough. Qlucore is helping scientists see those potential ‘eureka’ moments more clearly
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
Right-sized, not oversized: rethinking quality management technology for the UK's growing manufacturers (part II)
How the enterprise trap is set: familiar platforms, borrowed requirements and hidden validation costs can turn seemingly safe purchasing decisions into costly operational burdens
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Digital
Right-sized, not oversized: rethinking quality management technology for the UK's growing manufacturers (part I)
As the UK builds its own standalone device framework alongside continuing EU obligations, Mike King argues that manufacturers need quality management technology built for flexibility … not for the scale of the industry's largest players